Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 38, Issue 1, 1996, Pages 9-12

  Soda, Hiroshi ^a   Oka, Mikio ^a   Fukuda, Masaaki ^a   Kinoshita, Akitoshi ^a   Sakamoto, Akira ^a   Araki, Jun ^a   Fujino, Satoru ^a   Itoh, Naomi ^a   Watanabe, Koichi ^a   Kanda, Tetsuro ^a   Nakano, Masamoto ^a   Hara, Kohei ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Hematopoietic growth facotr; Lung cancer; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MITOMYCIN C; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINDESINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MORBIDITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCINS; NEUTROPENIA; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; VINDESINE;

EID: 9044237267     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050440     Document Type: Article

References (17)

1. Bronchud MH, Potter MR, Morgenstern G, Blasco MJ, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM (1988) In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer 58:64
2. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164
3. Funada H, Machi T, Ohtake S, Yoshida T, Matsuda T (1992) Effect of recombinant human granulocyte colony-stimulating factor (G-CSF) in the treatment of Pseudomonas aeruginosa bacteremia complicating hematologic malignancy: a preliminary study. J Jpn Assoc Infect Dis 66:76
4. Gabrilove J, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen HF, Alton K, Welte K, Souza L (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414
5. Hornung RL, Longo DL (1992) Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 80:77
6. Katoh M, Shirai T, Shikoshi K, Ishii M, Saito M, Kitagawa S (1992) Neutrophil kinetics shortly after initial administration of recombinant human granulocyte colony-stimulating factor: neutrophil alkaline phosphatase activity as an endogenous marker. Eur J Haematol 49:19
7. Maher D, Green M, Bishop J, Stuart-Harris R, Lieschke G, Wolf M, Sheridan W, Kefford R, Cebon J, Olver I, McKendrick J, Toner G, Lieschke M, Bradstock K, Cruickshank S, Hoffman E, Fox R, Morstyn G (1993) Randomized, placebo-controlled trial of filgrastim (r-metHuG-CSF) in patients with febrile neutropenia (FN) following chemotherapy (CT). Proc Am Soc Clin Oncol 12:434
8. Mayordomo JI, Rivera F, Diaz-Puente MT, Lianes MP, Lo'pez-Brea M, Lo'pez E, Paz-Ares L, Hitt R, Alonso S, Sevilla I, Rivas I, Corte's-Funes H (1993) Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: results of a randomized trial. Proc Am Soc Clin Oncol 12:437
9. Medical Computer Laboratory, Tokyo University Faculty of Medicine (1991) Software FISHER for Clinical Statistical Analysis (in Japanese). Nakayama Shoten, Tokyo
10. Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM (1992) Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 84:1201
11. Meisenberg BR, Davis TA, Melaragno AJ, Stead R, Monroy RL (1992) A comparison of therapeutic schedules for administering granulocyte colony-stimulating factor to nonhuman primates after high-dose chemotherapy. Blood 79:2267
12. Miles DW, Fogarty O, Ash CM, Rudd RM, Trask CWL, Spiro SG, Gregory WM, Ledermann JA, Souhami RL, Harper PG (1994) Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. J Clin Oncol 12:77
13. Mori K, Saitoh Y, Tominaga K (1993) Recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for non-small cell lung cancer. Eur J Cancer 29A:677
14. Morstyn G, Campbell L, Lieschke G, Layton JE, Maher D, O'Connor M, Green M, Sheridan W, Vincent M, Alton K, Souza L, McGrath K, Fox RM (1989) Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. J Clin Oncol 7:1554
15. Nissen C, Carbonare VD, Moser Y (1994) In vitro comparison of the biological potency of glycosylated versus nonglycosylated rG-CSF. Drug Invest 7:346
16. Shimizu E, Mukai J, Takakue T, Ogura T (1990) Circulating hematopoietic progenitors in patients with primary lung cancer. Jpn J Cancer Res 81:1293
17. Takada M, Fukuoka M, Ariyoshi Y, Furuse K, Niitani H, Ota K, Motomiya M, Hasegawa K, Tominaga K, Kuriyama T, Yoshida K, Kimura H, Kurita Y, Nakajima S, Nakai J, Ohta M, Yamamoto H (1992) The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer. Cancer Chemother Pharmacol 31:182